Cargando…
Evolocumab’s Long-Term Mortality Risk Unclear Due to Shortened Follow-Up of FOURIER
The FOURIER (Further Cardiovascular Outcomes Research with PCSK9 inhibition in Subjects with Elevated Risk) trial was conducted to study cardiovascular outcomes of treatment with evolocumab. The trial was terminated after a median follow-up of 2.2 years instead of the planned 3.6 years. We question...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer International Publishing
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8748321/ https://www.ncbi.nlm.nih.gov/pubmed/34008143 http://dx.doi.org/10.1007/s40256-021-00480-y |